Skip to content

SYK · STRYKER CORP

31 filings

10-K

SYK 10-K Annual Reports

STRYKER CORP - 31 annual reports

Filing record · 2016–202610-K1110-Q328-K125

2025
STRYKER CORP Annual Report, Year Ended Dec 31, 2025
Stryker Corporation reported strong performance for the fiscal year 2025, with net sales growing by 11.2% to $25,116 million, driven by robust increases in both its MedSurg and Neurotechnology segment (up 15.7%) and its Orthopaedics segment (up 4.3%). This growth was primarily fueled by increased unit volume across all businesses, with a notable contribution from the acquisition of Inari Medical, Inc. The company also demonstrated improved profitability, with gross profit increasing and operating income rising to $4,889 million, reflecting effective pricing strategies and favorable volume dynamics. Financially, Stryker maintained a healthy liquidity position, with significant cash flow from operations and substantial cash reserves. The company continued its capital allocation strategy, investing heavily in acquisitions totaling $4,960 million, while also returning capital to shareholders through dividends. Despite macroeconomic headwinds and ongoing investments in growth initiatives, Stryker has reaffirmed its commitment to innovation and expanding its product offerings, particularly in areas like robotic-assisted surgery and minimally invasive treatments, positioning it for continued success in the dynamic medical technology landscape.
Feb 11, 2026
2024
STRYKER CORP Annual Report, Year Ended Dec 31, 2024
Stryker Corporation's 2024 10-K filing highlights a year of robust growth and strategic acquisitions, underscoring its position as a global leader in medical technologies. The company reported a 10.2% increase in net sales, reaching $22.595 billion, driven by strong performance across both its MedSurg and Neurotechnology (up 11.1%) and Orthopaedics (up 8.9%) segments. This growth was fueled by increased unit volumes and, to a lesser extent, higher pricing, demonstrating resilience in a dynamic healthcare market. The company also completed several strategic acquisitions totaling $1.628 billion, further expanding its product portfolios and market reach. Financially, Stryker maintained healthy profitability with a gross profit margin of 63.9%. However, net earnings saw a slight decrease to $2.993 billion from $3.165 billion in the prior year, partly due to significant goodwill impairments related to its Spine business, amounting to $456 million, and a $362 million loss recognized on assets held for sale within the Spinal Implants business. Despite these charges, operating income remained strong. The company continued its commitment to capital allocation, investing in acquisitions, paying $1.219 billion in dividends, and maintaining a strong liquidity position with $3.743 billion in cash, cash equivalents, and marketable securities.
Feb 12, 2025
2023
STRYKER CORP Annual Report, Year Ended Dec 31, 2023
Stryker Corporation's 2023 10-K filing highlights robust top-line growth driven by strong unit volume increases across its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company reported net sales of $20.5 billion, an increase of 11.1% year-over-year, with constant currency growth at 11.6%. This growth was supported by product innovation and market expansion, including the acquisition of Cerus Endovascular. Profitability showed improvement, with operating income rising significantly, reflecting effective cost management and favorable pricing, though offset by increased manufacturing and supply chain costs. Stryker continues to prioritize its capital allocation strategy, investing in acquisitions, returning capital to shareholders through dividends, and engaging in share repurchases. The company maintains a strong liquidity position, with substantial cash from operations and access to credit markets. Key operational risks identified include supply chain disruptions, inflationary pressures, pricing pressures within the healthcare industry, and regulatory compliance. The company's robust risk management framework, including cybersecurity, is actively overseen by management and the Board of Directors.
Feb 14, 2024
2022
STRYKER CORP Annual Report, Year Ended Dec 31, 2022
Stryker Corporation reported net sales of $18.45 billion for the fiscal year ended December 30, 2022, a 7.8% increase from the prior year, or 11.0% in constant currency. The company's performance was driven by robust growth in its MedSurg and Neurotechnology segment, which increased 11.2% (14.1% in constant currency), while the Orthopaedics and Spine segment saw a more modest 3.5% increase (7.0% in constant currency). Despite top-line growth, profitability faced headwinds from inflationary pressures, primarily impacting labor, steel, and transportation costs, as well as electronic component shortages that constrained supply. These factors, coupled with unfavorable foreign exchange rates, led to a decrease in gross profit margin to 62.8% from 64.1% in the prior year. The company also recorded a significant goodwill impairment charge of $216 million related to its Spine business. Net earnings were $2.36 billion, or $6.17 per diluted share, representing an 18.3% increase year-over-year. Excluding certain items, adjusted net earnings per diluted share grew 2.8% to $9.34. Stryker continued its strategic capital allocation by investing $2.56 billion in acquisitions, notably the acquisition of Vocera Communications, Inc., and returning capital to shareholders through $1.05 billion in dividend payments. The company faces ongoing risks including supply chain disruptions, inflationary pressures, and regulatory complexities, particularly with the implementation of new medical device regulations in the EU and UK, and volume-based procurement programs in China.
Feb 10, 2023
2021
STRYKER CORP Annual Report, Year Ended Dec 31, 2021
Stryker Corporation's 2021 10-K filing reveals a strong recovery and growth trajectory following the disruptions of 2020. The company reported a 19.2% increase in net sales, reaching $17.1 billion, with organic growth of 13.4% driven by increased unit volume across most product lines. The company's strategic focus on key segments like MedSurg and Neurotechnology, and Orthopaedics and Spine, has yielded positive results. Significant growth was observed in the Orthopaedics and Spine segment, up 26.0%, indicating a robust rebound in elective procedures. Stryker continues to invest in innovation and acquisitions, with the notable pending acquisition of Vocera Communications, Inc. for approximately $3.1 billion, aiming to further enhance its market position and service offerings.
Feb 11, 2022
2020
STRYKER CORP Annual Report, Year Ended Dec 31, 2020
Stryker Corporation's 2020 10-K filing reveals a company navigating the complexities of the COVID-19 pandemic, which led to a 3.6% decline in net sales compared to 2019. Despite this, Stryker demonstrated resilience through strategic acquisitions, notably the significant purchase of Wright Medical Group N.V., which expanded its portfolio in trauma and extremities. The company maintained a strong focus on its core segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with MedSurg representing the largest segment by sales in 2020. Financially, Stryker reported net earnings of $1.6 billion, a decrease from the previous year, impacted by pandemic-related disruptions and increased interest expenses due to debt financing for acquisitions. However, operating cash flow remained robust, and the company prioritized its capital allocation strategy by investing heavily in acquisitions and continuing dividend payments, while suspending share repurchases for 2020 and 2021. Management highlighted the successful integration of acquisitions and ongoing efforts to drive innovation and operational efficiency amidst evolving market conditions and regulatory landscapes.
Feb 11, 2021
2019
STRYKER CORP Annual Report, Year Ended Dec 31, 2019
Stryker Corporation's 2019 Form 10-K report details a year of robust growth and strategic investments. The company achieved a reported net sales increase of 9.4%, reaching $14.88 billion, driven by strong performance across its Orthopaedics, MedSurg, and Neurotechnology and Spine segments. Excluding the impact of acquisitions and currency fluctuations, sales grew by 9.0% on a constant currency basis, primarily due to increased unit volume. Financially, Stryker reported net earnings of $2.08 billion, or $5.48 per diluted share. However, excluding certain non-recurring items and acquisition-related costs, adjusted net earnings grew by 13.0% to $3.14 billion. The company continued its capital allocation strategy, investing $802 million in acquisitions, paying $778 million in dividends, and repurchasing $307 million in stock. A significant development was the announcement of a definitive agreement to acquire Wright Medical Group N.V. for approximately $5.4 billion, expected to close in the second half of 2020, which will bolster Stryker's extremities and biologics offerings.
Feb 6, 2020
2018
STRYKER CORP Annual Report, Year Ended Dec 31, 2018
Stryker Corporation's 2018 10-K filing highlights a strong year characterized by significant revenue growth and strategic acquisitions. The company reported total net sales of $13.6 billion, representing a 9.3% increase over the prior year, driven by both organic growth and contributions from recent acquisitions. This growth was observed across all three reporting segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with Neurotechnology and Spine showing particularly robust expansion. Financially, Stryker demonstrated solid performance, with net earnings of $3.55 billion and diluted earnings per share of $9.34. The company continued its commitment to returning value to shareholders through a balanced capital allocation strategy that included substantial investments in acquisitions, dividend payments, and share repurchases. Key strategic moves during the year included the acquisitions of K2M Group Holdings, Inc. and Entellus Medical, Inc., aimed at strengthening their positions in the spine and neurotechnology markets, respectively. Looking ahead, Stryker faces various risks including regulatory scrutiny, competitive pressures, and the evolving healthcare landscape. However, the company's diversified product portfolio, focus on innovation, and strategic acquisitions position it well for continued growth and market leadership in the medical technology sector.
Feb 7, 2019
2017
STRYKER CORP Annual Report, Year Ended Dec 31, 2017
Stryker Corporation's 2017 10-K filing reveals a company demonstrating robust growth and strategic acquisitions in the medical technology sector. Total net sales increased by 9.9% to $12.44 billion, driven by strong performance in the MedSurg and Orthopaedics segments, with organic sales growth of 8.2% excluding acquisitions and currency impacts. The company's strategic focus on acquisitions is evident with the completion of NOVADAQ and the announced agreement to acquire Entellus Medical, underscoring its commitment to expanding its innovative product portfolio and market reach. While the company reported a decrease in net earnings to $1.02 billion from $1.65 billion in the prior year, largely impacted by a significant one-time tax expense related to the Tax Cuts and Jobs Act of 2017, the underlying operational performance remains strong. Adjusted net earnings per diluted share saw a healthy increase of 11.9%. Investors should note the ongoing legal proceedings, particularly related to the Rejuvenate and ABG II hip stems recall, which continues to represent a significant financial contingency, though the company has established reserves for these matters.
Feb 8, 2018
2016
STRYKER CORP Annual Report, Year Ended Dec 31, 2016
Stryker Corporation's 2016 Form 10-K highlights a strong year of growth, with net sales increasing by 13.9% to $11.3 billion, driven by robust performance across its business segments, particularly MedSurg and Neurotechnology and Spine. The company successfully executed its strategic capital allocation, investing significantly in acquisitions, notably Sage Products and Physio-Control, which are expected to bolster its offerings in intensive care disposable products and emergency medical equipment, respectively. While reporting net earnings of $1.65 billion, an increase from the previous year, investors should note the impact of recall charges related to the Rejuvenate and ABG II hip stems, which continue to affect the company's financial results, though at a reduced level compared to prior years. The company also demonstrated a commitment to shareholder returns through dividend payments. Looking ahead, Stryker is well-positioned with a diversified product portfolio and a continued focus on innovation, as evidenced by its consistent investment in research and development. The company faces a competitive landscape and regulatory scrutiny, common in the medical technology sector, but its strong financial position, including significant cash and credit facilities, provides a solid foundation for future growth and its strategic objectives, including further acquisitions and organic expansion. Investors should monitor the ongoing resolution of product liability matters and the company's ability to integrate recent acquisitions successfully.
Feb 9, 2017
2015
STRYKER CORP Annual Report, Year Ended Dec 31, 2015
Stryker Corporation's 2015 10-K filing reports on a year of moderate revenue growth, driven by increased unit volume and product mix, partially offset by pricing pressures and currency headwinds. The company's diverse medical technology portfolio, spanning Orthopaedics, MedSurg, and Neurotechnology & Spine, generated $9.95 billion in net sales. Net earnings saw a significant increase to $1.44 billion, largely due to a substantial reduction in recall charges compared to the prior year. Despite ongoing investments in R&D and strategic acquisitions, the company maintained a strong financial position with robust operating cash flow and significant liquidity. Investors should note the ongoing impact of the Rejuvenate and ABG II hip stem recall, which continues to incur charges, though at a reduced level. The company also highlighted its capital allocation strategy prioritizing acquisitions, dividends, and share repurchases.
Feb 11, 2016
2014
STRYKER CORP Annual Report, Year Ended Dec 31, 2014
Stryker Corporation's 2014 Form 10-K reveals a company with robust revenue growth, achieving $9.675 billion in net sales, a 7.3% increase year-over-year. This growth was driven by strong performance across its three key segments: Orthopaedics, MedSurg, and Neurotechnology and Spine, with particular strength noted in instruments, trauma and extremities, and neurotechnology products. The company continued its strategic focus on acquisitions, investing $916 million in 2014 to expand its product offerings and market reach. However, net earnings experienced a significant decline of 48.8% to $515 million, largely impacted by substantial recall charges related to hip stems, totaling $761 million. Despite this, Stryker maintained a strong financial position with $5 billion in cash, cash equivalents, and marketable securities, indicating good liquidity. The company also demonstrated its commitment to returning value to shareholders through dividend payments and share repurchases, while continuing to invest in research and development to fuel future innovation.
Feb 12, 2015
2013
STRYKER CORP Annual Report, Year Ended Dec 31, 2013
Stryker Corporation reported total revenues of $9.02 billion for the fiscal year ended December 30, 2013, a 4.2% increase over the prior year. Net earnings for the period were $1.01 billion, a decrease of 22.5% compared to $1.30 billion in 2012. This decline in net earnings was significantly influenced by charges related to product recalls, specifically the Rejuvenate and ABG II hip stems, as well as acquisition and integration costs. The company demonstrated revenue growth across its three main segments: Reconstructive, MedSurg, and Neurotechnology and Spine, driven primarily by increased unit volumes, particularly in trauma and extremities products, neurotechnology, hips, and endoscopy. Stryker continued its strategic acquisition approach, notably acquiring MAKO Surgical Corp. for approximately $1.68 billion to enhance its robotic-assisted surgery capabilities and Trauson Holdings Company Limited for $751 million to expand its presence in China and the value segment of emerging markets. The company also announced its intent to acquire Patient Safety Technologies, Inc. in early 2014. Despite ongoing legal and regulatory matters, including reserves for the hip stem recalls totaling between $790 million and $1.235 billion, Stryker maintained a strong balance sheet with significant cash and cash equivalents. The company also increased its dividend payments and continued share repurchases, signaling confidence in its financial position and future prospects.
Feb 13, 2014
2012
STRYKER CORP Annual Report, Year Ended Dec 31, 2012
Stryker Corporation's 2012 10-K filing reveals a company with robust revenue growth and diverse product segments, including Reconstructive, MedSurg, and Neurotechnology and Spine. In 2012, the company generated $8.66 billion in net sales and $1.30 billion in net earnings. The Reconstructive segment, primarily focused on joint replacements, showed steady growth, while MedSurg, encompassing surgical equipment and systems, also saw increases. The Neurotechnology and Spine segment experienced significant growth, largely driven by strategic acquisitions that expanded its product offerings in neurovascular and spinal devices. The company highlights its commitment to innovation, with ongoing research and development investments, and strategic acquisitions to bolster its portfolio. However, Stryker also faces several risks, including potential impacts from healthcare reform legislation, particularly the 2.3% medical device excise tax, pricing pressures due to cost containment measures, and significant legal and regulatory risks, including ongoing product liability lawsuits and investigations. Despite these challenges, Stryker demonstrated strong operating cash flow and maintained a healthy liquidity position.
Feb 27, 2013
2011-A
STRYKER CORP Annual Report (Amendment), Year Ended Dec 31, 2011
This filing is a limited-scope amendment to Stryker's 2011 annual report. It contains only Item 9A (Controls and Procedures), the auditor's internal control report, and exhibit listings. It does not include the financial statements, MD&A, or segment results, which were previously filed with the original 10-K on February 13, 2012. Management concluded that Stryker's disclosure controls and internal control over financial reporting were effective as of December 31, 2011, and Ernst & Young issued an unqualified opinion on internal control on the same basis. The most important disclosure for investors is the scope carve-out. Management excluded the Neurovascular business acquired from Boston Scientific in 2011 from its internal control assessment, as the SEC permits for a one-year period after an acquisition. That business represented 13% of total assets, 7% of shareholders' equity, and 4% of 2011 revenues. Stryker is also implementing new ERP systems at several divisions, including Canada, Europe, and Neurovascular, and states it does not expect this to adversely affect internal control. The filing also reflects a leadership transition. The Vice President and Chief Financial Officer was serving as Interim Chief Executive Officer, following the departure of the prior President and CEO. The exhibit index shows the acquisition agreement with Boston Scientific, the 2010 credit agreement with Bank of America, and the 2010 and 2011 note indentures, which are the key contractual documents for the acquisition and debt structure.
Apr 24, 2012
2011
STRYKER CORP Annual Report, Year Ended Dec 31, 2011
Stryker Corporation reported robust revenue growth in 2011, driven by strong performance across its three key segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The company's strategic acquisitions, particularly the significant Neurovascular division acquisition from Boston Scientific, played a crucial role in expanding its market presence and product portfolio, especially in the neurotechnology space. Despite a challenging economic environment and increased R&D investments, Stryker demonstrated solid operational execution, with notable revenue increases in both domestic and international markets. The company also managed its costs effectively, although certain one-time charges related to restructuring and acquisition integration impacted reported net earnings. Stryker's financial position remains strong, supported by healthy operating cash flow and a well-managed debt structure, allowing for continued investment in innovation and shareholder returns through dividends and share repurchases.
Feb 13, 2012
2010
STRYKER CORP Annual Report, Year Ended Dec 31, 2010
Stryker Corporation's 2010 Form 10-K highlights a year of solid growth, with total net sales increasing by 9% to $7.32 billion. This growth was driven by a combination of increased unit volume, strategic acquisitions, and favorable foreign currency exchange rates, partially offset by pricing changes. The company's performance was supported by strong sales in both its Orthopaedic Implants and MedSurg Equipment segments. The Orthopaedic Implants segment saw a 5% increase in sales, primarily driven by hip, knee, and trauma implant systems, while the MedSurg Equipment segment experienced a significant 16% jump, bolstered by surgical equipment, navigation systems, and patient handling products. The company also made strategic acquisitions throughout the year, including key assets in the neurovascular market, which are expected to enhance its product portfolio and market presence. Financially, Stryker demonstrated robust operational cash flow and a strong balance sheet, enabling it to fund acquisitions, dividends, and stock repurchases. Despite some ongoing legal and regulatory matters, the company maintained effective internal controls and expressed confidence in its ability to fund future operations and growth initiatives.
Feb 18, 2011
2009
STRYKER CORP Annual Report, Year Ended Dec 31, 2009
Stryker Corporation's 2009 10-K report reveals a company with stable net sales of $6.72 billion, showing minimal growth year-over-year, largely due to the economic downturn impacting its MedSurg Equipment segment. Despite this, the Orthopaedic Implants segment demonstrated resilience with a 4% increase in sales, driven by strong performance in hip, knee, trauma, and spinal implant systems. The company made a significant strategic acquisition of Ascent Healthcare Solutions for $525 million in cash, aiming to bolster its MedSurg segment. Stryker also managed its expenses effectively, reducing R&D spending as a percentage of sales and controlling SG&A expenses, which, combined with a patent litigation gain, helped offset some of the impacts from restructuring charges and higher cost of sales. Investors should note the ongoing regulatory scrutiny, including FDA warning letters at several facilities, though one has been resolved. The company also highlighted its strong liquidity position and access to credit facilities to fund future operations and growth initiatives.
Feb 26, 2010
2008
STRYKER CORP Annual Report, Year Ended Dec 31, 2008
Stryker Corporation's 2008 10-K filing reveals a robust year of growth, with net sales reaching $6.7 billion, a 12% increase over 2007. This growth was driven by strong performance across both its Orthopaedic Implants and MedSurg Equipment segments, with international sales showing a notable 13% increase. Despite a challenging economic climate, particularly impacting hospital capital budgets in the latter half of the year, Stryker demonstrated resilience, with significant sales increases in key areas like knee implants (14%), trauma implants (18%), and patient handling equipment (18%). The company also reported a 16% increase in net earnings from continuing operations to $1.15 billion. Management highlighted its focus on innovation and new product introductions, such as the Tritanium Primary Hip System and the S3 Med/Surg Hospital Bed, as critical to its growth strategy. While the company faced some regulatory challenges, including warning letters related to quality systems, it actively cooperated with authorities to address these issues. Stryker also continued its share repurchase program, underscoring its commitment to returning value to shareholders.
Feb 20, 2009
2007-A
STRYKER CORP Annual Report (Amendment), Year Ended Dec 31, 2007
This filing for Stryker Corporation (SYK) pertains to its 2007 annual report, specifically an amendment (10-K/A) filed on March 3, 2008. The filing primarily incorporates by reference information from the company's 2008 proxy statement regarding its directors and corporate governance. It also provides details on the company's executive officers as of January 31, 2008, including their roles, tenure, and prior experience. Investors can gain insight into the leadership team's background, which can be a crucial factor in assessing management's capabilities and strategic direction. The report highlights the established corporate governance framework, with key documents such as Corporate Governance Guidelines, committee charters (Audit, Governance and Nominating, Compensation), and the Code of Ethics readily available on the company's website and upon written request. This emphasis on transparency and structured governance is a positive signal for investors concerned with ethical business practices and oversight. The filing also lists the certifications required by Rule 13a-14(a) for the Principal Executive Officer and Principal Financial Officer, underscoring compliance with regulatory standards.
Mar 3, 2008
2007
STRYKER CORP Annual Report, Year Ended Dec 31, 2007
Stryker Corporation's 2007 Form 10-K details a year of robust growth, with net sales increasing 17% to $6.0 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company experienced broad-based sales growth across key product lines, including hip and knee implants, trauma systems, and surgical equipment. This growth was fueled by new product introductions and continued investment in research and development, which represented 6.3% of sales. Operationally, Stryker demonstrated improved profitability, with net earnings from continuing operations up 28% year-over-year. The company successfully managed its cost of sales and selling, general, and administrative expenses relative to sales, indicating operational efficiency. While facing some regulatory scrutiny, including FDA warning letters regarding quality systems, Stryker is actively addressing these concerns and maintains a positive outlook for 2008, projecting a 22% increase in diluted net earnings per share. The company also reports a healthy financial position with ample liquidity and borrowing capacity.
Feb 28, 2008
2006
STRYKER CORP Annual Report, Year Ended Dec 31, 2006
Stryker Corporation's 2006 10-K filing reveals a robust year of growth and strategic acquisitions, positioning the company as a leader in medical technology. The company reported net sales of $5.41 billion, an 11% increase year-over-year, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. Significant product launches and the successful integration of recent acquisitions, including Sightline Technologies, PlasmaSol, and eTrauma, contributed to this growth. Financially, Stryker demonstrated solid profitability, with net earnings of $777.7 million, a 21% increase from the previous year. The company's investment in research and development (R&D) increased to 6.0% of sales, reflecting a commitment to innovation and future product pipelines, particularly in advanced implant technologies and surgical equipment. The company maintained a strong balance sheet with substantial cash and marketable securities, providing ample resources for ongoing operations, potential future acquisitions, and shareholder returns.
Feb 28, 2007
2005
STRYKER CORP Annual Report, Year Ended Dec 31, 2005
Stryker Corporation's 2005 10-K report highlights a strong year of growth, with net sales increasing 14% to $4.87 billion, driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company completed a significant repatriation of $722 million in foreign earnings, leveraging the American Jobs Creation Act, which will be reinvested domestically. Strategic acquisitions played a key role, with the integration of PlasmaSol Corp. and eTrauma.com Corp. bolstering Stryker's product offerings in sterilization equipment and digital imaging, respectively. The company also made substantial investments in research and development, increasing R&D spending to 5.7% of sales, underscoring its commitment to innovation. Looking ahead, Stryker projected continued growth and earnings per share expansion in 2006, signaling confidence in its market position and product pipeline.
Mar 7, 2006
2004
STRYKER CORP Annual Report, Year Ended Dec 31, 2004
Stryker Corporation's 2004 Form 10-K highlights a year of significant growth and strategic acquisitions. The company demonstrated robust top-line expansion with net sales increasing by 18% to $4.26 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volume, favorable foreign currency exchange rates, and strategic price adjustments. A notable event was the acquisition of SpineCore, Inc., which is expected to bolster Stryker's position in the growing spinal implant market. Operationally, Stryker reported an increase in operating income and net earnings, although reported net earnings saw a smaller increase due to a significant charge for purchased in-process research and development related to the SpineCore acquisition. Excluding this one-time charge, adjusted net earnings showed a substantial increase of 29%, underscoring the underlying strength of the business. The company also continued its investment in research and development, with expenditures increasing by 17% to support new product launches and future growth initiatives.
Mar 2, 2005
2003
STRYKER CORP Annual Report, Year Ended Dec 31, 2003
Stryker Corporation's 2003 Form 10-K report showcases a company with robust growth and a diversified product portfolio in the orthopaedics and medical technology sectors. The company achieved a significant 20% increase in net sales, reaching $3.6 billion, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. This growth was fueled by increased unit volume, higher selling prices, and favorable foreign currency exchange rates. Stryker's strategic acquisitions, such as the Surgical Dynamics Inc. spinal implant business, further bolstered its product offerings and market position. Financially, Stryker demonstrated strong profitability, with net earnings increasing by 31% to $453.5 million. The company also managed its debt effectively, with total borrowings declining significantly. Looking ahead, Stryker expressed optimism for 2004, anticipating continued sales growth and a focus on investing in future business expansion, including potential acquisitions. The company's commitment to research and development, evidenced by increased R&D spending, and its expanding international presence highlight its strategy for sustained long-term growth and market leadership.
Mar 12, 2004
2002
STRYKER CORP Annual Report, Year Ended Dec 31, 2002
Stryker Corporation's 2002 10-K report highlights a strong year of growth, with net sales increasing by 16% to $3,011.6 million. This growth was driven by robust performance in both its Orthopaedic Implants and MedSurg Equipment segments, with particular strength in reconstructive, trauma, and spinal implants, as well as powered surgical instruments and endoscopic systems. The company also successfully integrated several strategic acquisitions, including Surgical Dynamics Inc. (SDI), which expanded its spinal product offerings. Financially, Stryker demonstrated improved profitability, with net earnings up 29% year-over-year, and effective management of expenses, including a decrease in research, development, and engineering as a percentage of sales due to the commercial launch of its OP-1 product. The company's liquidity remains strong, supported by significant cash flow from operations and substantial available borrowing capacity, enabling continued investment in product development and strategic acquisitions.
Mar 14, 2003
2001
STRYKER CORP Annual Report, Year Ended Dec 31, 2001
Stryker Corporation's 2001 10-K report highlights a year of significant growth, with net sales increasing by 14% to $2.6 billion. This growth was driven by a robust performance in both its Orthopaedic Implants and MedSurg Equipment segments. The company successfully navigated a dynamic market, marked by strategic acquisitions and a strong focus on research and development, evidenced by a 16% increase in R&D expenses. Financially, Stryker demonstrated improved profitability and liquidity. Net earnings saw a substantial increase of 21% to $267 million. The company also enhanced its financial flexibility through refinancing its credit facilities. Despite ongoing healthcare cost containment measures, Stryker's commitment to innovation and its broad product portfolio position it well for continued expansion in the specialty surgical and medical products market.
Mar 15, 2002
1995
STRYKER CORP Annual Report, Year Ended Dec 31, 1995
Stryker Corporation's 1995 10-K shows a company in strong growth, with net sales up 28% to $871.9 million (from $681.9 million) and net earnings up 20% to $87.0 million, or $1.80 per share. Growth was driven heavily by the August 1994 consolidation of Japanese distributor Matsumoto Medical Instruments (51% owned), which contributed roughly 15 points of sales growth, and by Stryker Surgical products (orthopaedic implants, endoscopy, powered instruments), which rose 21% to $608.6 million. International sales reached 45% of revenue, up from 41%. Operating margin improved to 18.0% from 17.7%, although the consolidation of lower-margin distribution revenue diluted SG&A, which rose to 34.6% of sales from 32.5%, and the effective tax rate rose to 41.0% due to Japanese taxes. The balance sheet remained strong, with cash and marketable securities of $264.6 million, working capital of $448.8 million, a current ratio of 3.6, and total debt of about $100 million, mostly yen-denominated bank loans that hedge the Matsumoto investment. Operating cash flow was $111.5 million. Management flagged several watch items: Matsumoto's distributed-products sales fell 29% in Q4 1995 as distribution agreements were terminated and are expected to decline further in 1996; inventory days rose slightly to 133; and the company's OP-1 bone growth device remains in clinical trials with no PMA filed. Investors should also note a pending court award of $72.7 million against Intermedics, which is under appeal and not recognized in the financials. Overall, the filing describes a company with accelerating revenue growth, expanding margins in its core surgical business, a fortress balance sheet, and a few identifiable risks: dependence on international and Japanese operations, a possible drop in distributed-product revenue, and an uncertain appeal of a large contingent gain.
Mar 28, 1996
1994-A
STRYKER CORP Annual Report (Amendment), Year Ended Dec 31, 1994
Stryker Corporation's 1994 10-K shows a company in strong growth mode, with net sales rising 22% to $681.9 million and net earnings up 20% to $72.4 million, or $1.50 per share. Much of the top-line expansion was inorganic: the August 1994 consolidation of Matsumoto Medical Instruments, its Japanese distributor, contributed roughly 12 points of the sales increase. Underlying domestic sales grew a more modest 7%, slowed by uncertainty over U.S. health care reform, while international sales rose 54% and now represent 41% of revenue. Operating margin improved to 17.7% from 16.5%, helped by cost-of-sales gains and lower R&D intensity, though selling, general and administrative expense climbed to 32.5% of sales from 30.9%, reflecting the distributor-heavy Matsumoto cost structure. The balance sheet changed materially. Total assets nearly doubled to $768.0 million, driven by the Matsumoto deal, which was financed largely with yen-denominated bank debt. Long-term debt rose to $95.3 million from $31.3 million, though the interest rate on the principal loans was fixed at 4.17% via swaps and the company still held $202.0 million in cash and marketable securities. Working capital rose to $361.3 million. Accounts receivable and inventories grew faster than sales, with days sales outstanding increasing to 67 from 47, a trend investors should monitor for collection quality. Return on average equity held at a healthy 22.4%. Looking ahead, the key investor considerations are the durability of growth once the Matsumoto consolidation laps, the sensitivity of domestic medical device demand to health care reform outcomes, and the company's ability to convert its expanded international footprint into sustained margin improvement. The company also disclosed a $152.6 million pool of undistributed foreign earnings intended for indefinite reinvestment overseas, and a 10-year financial history showing consistent compounding of sales and earnings since 1985.
May 5, 1995
1994
STRYKER CORP Annual Report, Year Ended Dec 31, 1994
Stryker Corporation's 1994 10-K shows a company in strong growth, with net sales up 22% to $681.9 million (from $557.3 million) and net earnings up 20% to $72.4 million, or $1.50 per share. Operating income rose 31% to $120.5 million, and the operating margin expanded to 17.7% from 16.5%, driven mainly by the lower cost-of-sales ratio (44.0% vs. 46.1%) and the consolidation of Japanese distributor Matsumoto Medical Instruments, in which Stryker raised its stake from 20% to 51% in August 1994. Matsumoto alone contributed about 12 points of sales growth, and international sales rose to 41% of the total from 32%. Surgical products (orthopaedic implants, powered instruments, endoscopy) make up 80% of sales, and Medical products (stretchers, beds, physical therapy) make up 20%. The balance sheet and cash flow were also strong, though the period had some notable changes. Operating cash flow was $97.7 million, and cash plus marketable securities reached $202.0 million. Total assets nearly doubled to $768.0 million, largely from the Matsumoto consolidation, and long-term debt rose to $95.3 million, mostly yen-denominated loans swapped to a fixed 4.17% rate. Receivables and inventory grew faster than sales, with days sales outstanding up to 67 from 47, which investors should watch. Management attributes much of this to Matsumoto's distributor-style working capital and says domestic sales grew only 7% amid U.S. health care reform uncertainty. The filing also shows a company that depends heavily on new product development and international expansion. R&D spending rose 9% to $39.6 million, and the company holds roughly 100 U.S. patents and 50 foreign patents. Stryker has not yet entered the U.S. spinal implant market, and it has a CE-mark deadline in the EU in 1998. The company reported no material legal losses and no customer above 10% of 1994 sales. Its stock trades on Nasdaq under STRY, and it paid an $0.08 annual dividend.
Mar 24, 1995
1993
STRYKER CORP Annual Report, Year Ended Dec 31, 1993
Stryker Corporation (NASDAQ: STRY) closed 1993 with strong top-line and earnings growth. Net sales rose 17% to $557.3 million from $477.1 million, and net earnings increased 26% to $60.2 million, or $1.25 per share, from $47.7 million ($1.00). Operating margin widened to 16.5% from 15.4%, driven by a lower cost of sales (46.1% of sales vs. 46.5%) and SG&A that fell to 30.9% of sales from 31.3%. Growth was led by Surgical products (orthopaedic implants, endoscopy, powered instruments), which rose 13% to $447.0 million, while Medical products (specialty stretchers/beds and physical therapy) jumped 33% to $110.3 million. International sales reached 32% of total revenue, and domestic sales grew 14% despite headwinds from U.S. health care reform uncertainty and purchaser shifts toward lower-cost implants. Balance sheet strengthened meaningfully. Cash and marketable securities totaled $152.6 million at year-end, and working capital rose to $214.0 million. Stockholders' equity grew to $288.4 million, and return on average equity held at 23.1%. The company took on $31.3 million in long-term debt, mostly a five-year yen-denominated loan used to finance a 20% stake in Japanese distributor Matsumoto Medical Instruments (about $33 million, accounted for under the equity method). Inventory days improved to 114 from 130, and receivable days fell to 47 from 52, indicating better working capital management. Operating cash flow was $86.1 million, up from $50.7 million. For investors, the key points are consistent double-digit growth, expanding margins, and a healthy balance sheet, offset by dependence on the orthopaedic segment, exposure to health care cost-containment policy, and a sizable 12% of sales tied to a single customer (Matsumoto). The company also continued to invest heavily in R&D, which rose 12% to $36.2 million.
Mar 24, 1994